Britain and America have agreed to a major bilateral deal that will keep no levies on British medicine shipments going into the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that duties on these vital products will remain at zero for a duration of three years.
This deal follows previous statements to hike import taxes on patented pharmaceutical products, with increases mentioned reaching double the cost.
"This deal with the UK bolsters the international landscape for innovative medicines and establishes much-needed balance to transatlantic drug exports," an announcement noted.
Trade Importance
Drugs represent one of the UK's biggest exports to the United States, which is easily the primary destination for leading companies like GSK and AstraZeneca.
Export figures show that in the one-year period leading up to last September, the UK exported drugs totaling £11.1bn to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This agreement protects employment, increases capital expenditure and facilitates the UK to become a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Key NHS Changes
The pact includes several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to double overall public funding on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates exceeded twenty percent.
Industry Background
The pact takes place against a protracted row between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were exacerbated by arguments that American patients were paying a premium for the identical medicines than consumers in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar investments have been directed toward projects in the United States.
One official acknowledged that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
